e-learning
resources
Vienna 2003
Monday 29.09.2003
Lung cancer: clinical and biological presentation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Immunopathology of advanced forms of NSCLC: the influence of induction chemotherapy
O. A. Sukhoversha (Dnipropetrovsk, Ukraine)
Source:
Annual Congress 2003 - Lung cancer: clinical and biological presentation
Session:
Lung cancer: clinical and biological presentation
Session type:
Poster Discussion
Number:
2288
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. A. Sukhoversha (Dnipropetrovsk, Ukraine). Immunopathology of advanced forms of NSCLC: the influence of induction chemotherapy. Eur Respir J 2003; 22: Suppl. 45, 2288
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Role of adjuvant/neoadjuvant treatment in stage I NSCLC
Source: International Congress 2014 – Current therapeutic options in stage I non-small cell lung cancer (NSCLC)
Year: 2014
Effect of adjuvant chemotherapy on lung function in early stage NSCLC
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011
Systemic treatment of advanced NSCLC
Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Year: 2007
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Quality of life in patients with advanced forms of NSCLC and breast cancer after induction chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 324s
Year: 2005
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017
Year: 2018
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy?
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004
Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Non-small cell lung cancer - oral navelbine single-agent chemotherapy in elderly patient advanced stage or metastatic disease
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004
The correlation between clinical and pathomorphological impacts of induction chemotherapy and long-term results of multimodality treatment for IIIA stage non-small cell lung cancer
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Indcution chemotherapy and radiotherapy
vs.
induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97
Source: Eur Respir J 2006; 28: Suppl. 50, 833s
Year: 2006
Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
CON: maintenance chemotherapy after induction chemotherapy for advanced nonsmall cell lung cancer
Source: Annual Congress 2011 - Pro/Con debate: Maintenance chemotherapy after induction chemotherapy for advanced nonsmall cell lung cancer
Year: 2011
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept